<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874431</url>
  </required_header>
  <id_info>
    <org_study_id>16243</org_study_id>
    <secondary_id>2012-004179-38</secondary_id>
    <nct_id>NCT01874431</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</brief_title>
  <acronym>ARTS-DN</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was&#xD;
      safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy.&#xD;
      These treatment doses were compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2013</start_date>
  <completion_date type="Actual">August 7, 2014</completion_date>
  <primary_completion_date type="Actual">July 9, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of UACR at Day 90 to UACR at Baseline</measure>
    <time_frame>Baseline and Day 90±2</time_frame>
    <description>Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 90 in Serum Potassium</measure>
    <time_frame>Baseline and Day 90±2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 90 in eGFR</measure>
    <time_frame>Baseline and Day 90±2</time_frame>
    <description>An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)</measure>
    <time_frame>Baseline and Day 90±2</time_frame>
    <description>The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). &quot;Effects of Kidney disease&quot; subscore was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)</measure>
    <time_frame>Baseline and Day 90±2</time_frame>
    <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">823</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862) (1.25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.25 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)(2.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)(5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)(7.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862) (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862) (15 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)(20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg dose oral once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral dose once daily for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY94-8862)</intervention_name>
    <arm_group_label>Finerenone (BAY94-8862) (1.25 mg)</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862) (10 mg)</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862) (15 mg)</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)(2.5 mg)</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)(20 mg)</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)(5 mg)</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)(7.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 years and older.The lower age limit may be higher if legally&#xD;
             required in the participating country&#xD;
&#xD;
          -  Women of childbearing potential can only be included in the study if a pregnancy test&#xD;
             is negative and if they agree to use adequate contraception when sexually active.&#xD;
&#xD;
          -  Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria&#xD;
&#xD;
               -  are on oral antidiabetics and / or insulin,&#xD;
&#xD;
               -  have a documented fasting glucose &gt;/= 7.0 mmol/L in the medical history,&#xD;
&#xD;
               -  have a 2 hour plasma glucose &gt;/=11.1 mmol/L during an oral glucose tolerance test&#xD;
                  in the medical history, or&#xD;
&#xD;
               -  have a glycated hemoglobin (HbA1c) &gt;/=6.5% [National Glycohemoglobin&#xD;
                  Standardization Program (NGSP) / Diabetes Control and Complications Trial (DCCT)]&#xD;
                  in the medical history or at the run-in visit&#xD;
&#xD;
          -  Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of&#xD;
             the following criteria:&#xD;
&#xD;
               -  Persistent very high albuminuria defined as urinary albumin-to-creatine ratio&#xD;
                  (UACR) of &gt;/=300 mg/g ( &gt;/= 34 mg/mmol) in 2 out of 3 first morning void samples&#xD;
                  and estimated glomerular filtration rate (eGFR) &gt;/=30 mL/min/1.73 m² but &lt; 90&#xD;
                  mL/min/1.73m² (Chronic Kidney Disease Epidemiology Collaboration, CKD EPI) (mL =&#xD;
                  milliliter; min = minute; m2 = square meter; g = gram; mmol = millimole) or&#xD;
&#xD;
               -  Persistent high albuminuria defined as UACR of &gt;/=30 mg/g but &lt;300 mg/g in&#xD;
                  (&gt;/=3.4mg/mmol but &lt;34 mg/mmol) in 2 out of 3 first morning void samples and eGFR&#xD;
                  &gt;/=30 mL/min/1.73 m² but &lt; 90 mL/min/1.73m²&#xD;
&#xD;
          -  Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or&#xD;
             angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to&#xD;
             this therapy for at least 4 weeks prior to the screening visit&#xD;
&#xD;
          -  Serum potassium &lt;/= 4.8 mmol/L at both the run-in visit and the screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-diabetic renal disease&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) &gt;12% at the run-in visit or the screening visit&#xD;
&#xD;
          -  UACR &gt;3000 mg/g (339mg/mmol) in any of the urinary first morning void samples at the&#xD;
             run-in visit or screening visit&#xD;
&#xD;
          -  Hypertension with mean sitting systolic blood pressure (SBP) &gt;/=180 mmHg or mean&#xD;
             sitting diastolic blood pressure (DBP) &gt;/=110 mmHg at the run-in visit or mean supine&#xD;
             SBP &gt;/=160 mmHg or mean sitting DBP &gt;/=100 mmHg at the screening visit&#xD;
&#xD;
          -  Subjects with a clinical diagnosis of heart failure with reduced ejection fraction&#xD;
             (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the run-in&#xD;
             visit&#xD;
&#xD;
          -  Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or&#xD;
             potassium-sparing diuretic&#xD;
&#xD;
          -  Dialysis for acute renal failure within the previous 6 months prior to the run-in&#xD;
             visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-3858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reservoir</city>
        <state>Victoria</state>
        <zip>3073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>3086</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5026</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Pölten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lukovit</city>
        <zip>5770</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruse</city>
        <zip>7003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <zip>L1E 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2H 5Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H 3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chrudim</city>
        <zip>537 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koprivnice</city>
        <zip>742 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krnov</city>
        <zip>794 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillerød</city>
        <zip>DK-3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holbaek</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holstebro</city>
        <zip>DK-7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland-Pfalz</state>
        <zip>67059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuwied</city>
        <state>Rheinland-Pfalz</state>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Papa</city>
        <zip>8500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>6203854</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>6937947</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza-Brianza</city>
        <state>Lombardia</state>
        <zip>20832</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>AlMERE</city>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5600 PD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamar</city>
        <zip>2326</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ålesund</city>
        <zip>6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-822</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klipsruit West</city>
        <state>Gauteng</state>
        <zip>1812</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenasia South</city>
        <state>Gauteng</state>
        <zip>1829</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newtown</city>
        <state>Gauteng</state>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4037</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4067</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merebank</city>
        <state>Kwazulu-Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tongaat</city>
        <state>Kwazulu-Natal</state>
        <zip>4400</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodwood</city>
        <state>Western Cape</state>
        <zip>7460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kristianstad</city>
        <zip>29185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>113 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>753 19</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <results_reference>
    <citation>Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.</citation>
    <PMID>26325557</PMID>
  </results_reference>
  <results_reference>
    <citation>Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x.</citation>
    <PMID>31583611</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10:CD007004. doi: 10.1002/14651858.CD007004.pub4.</citation>
    <PMID>33107592</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <results_first_submitted>April 15, 2021</results_first_submitted>
  <results_first_submitted_qc>April 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <disposition_first_submitted>June 4, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 4, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 1, 2015</disposition_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 148 study centers in 23 countries, from 12 June 2013 (first participant, first visit) to 07 August 2014 (last participant, last visit). The randomization was stratified by region (Europe, North America, Asia, others [Australia, Israel, and South Africa]), and type of albuminuria at screening (very high or high albuminuria).</recruitment_details>
      <pre_assignment_details>Of 1501 participants screened, 823 were randomized at 128 study centers and 678 were screening failures. The reasons were not fulfilled inclusion-/exclusion criteria's (635 participants), withdrawal by participants (37 participants), adverse event (3 participants), physician decision (2 participants), logistical difficulties (1 participant) and lost to follow-up (1 participant).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Finerenone (BAY94-8862) (1.25 mg)</title>
          <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="P2">
          <title>Finerenone (BAY94-8862) (2.5 mg)</title>
          <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="P3">
          <title>Finerenone (BAY94-8862) (5 mg)</title>
          <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="P4">
          <title>Finerenone (BAY94-8862) (7.5 mg)</title>
          <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="P5">
          <title>Finerenone (BAY94-8862) (10 mg)</title>
          <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="P6">
          <title>Finerenone (BAY94-8862) (15 mg)</title>
          <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="P7">
          <title>Finerenone (BAY94-8862) (20 mg)</title>
          <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="P8">
          <title>Placebo</title>
          <description>Placebo tablet once daily in the morning for 90 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="125"/>
                <participants group_id="P7" count="120"/>
                <participants group_id="P8" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="125"/>
                <participants group_id="P7" count="119"/>
                <participants group_id="P8" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="91"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="114"/>
                <participants group_id="P7" count="112"/>
                <participants group_id="P8" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Logistical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set (SAF): all randomized subjects who took at least one dose of study drug and with data after beginning of treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Finerenone (BAY94-8862) (1.25 mg)</title>
          <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B2">
          <title>Finerenone (BAY94-8862) (2.5 mg)</title>
          <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B3">
          <title>Finerenone (BAY94-8862) (5 mg)</title>
          <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B4">
          <title>Finerenone (BAY94-8862) (7.5 mg)</title>
          <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B5">
          <title>Finerenone (BAY94-8862) (10 mg)</title>
          <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B6">
          <title>Finerenone (BAY94-8862) (15 mg)</title>
          <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B7">
          <title>Finerenone (BAY94-8862) (20 mg)</title>
          <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="B8">
          <title>Placebo</title>
          <description>Placebo tablet once daily in the morning for 90 days.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="97"/>
            <count group_id="B5" value="98"/>
            <count group_id="B6" value="125"/>
            <count group_id="B7" value="119"/>
            <count group_id="B8" value="94"/>
            <count group_id="B9" value="821"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="92"/>
                    <count group_id="B3" value="100"/>
                    <count group_id="B4" value="97"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="125"/>
                    <count group_id="B7" value="119"/>
                    <count group_id="B8" value="94"/>
                    <count group_id="B9" value="821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.91" spread="9.57"/>
                    <measurement group_id="B2" value="64.86" spread="9.09"/>
                    <measurement group_id="B3" value="63.31" spread="8.79"/>
                    <measurement group_id="B4" value="63.73" spread="10.04"/>
                    <measurement group_id="B5" value="64.94" spread="9.62"/>
                    <measurement group_id="B6" value="63.95" spread="8.34"/>
                    <measurement group_id="B7" value="64.70" spread="9.26"/>
                    <measurement group_id="B8" value="63.26" spread="8.68"/>
                    <measurement group_id="B9" value="64.21" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="92"/>
                    <count group_id="B3" value="100"/>
                    <count group_id="B4" value="97"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="125"/>
                    <count group_id="B7" value="119"/>
                    <count group_id="B8" value="94"/>
                    <count group_id="B9" value="821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="98"/>
                    <measurement group_id="B7" value="89"/>
                    <measurement group_id="B8" value="69"/>
                    <measurement group_id="B9" value="639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline UACR</title>
          <description>Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was determined from 3 first morning void samples taken on 3 consecutive days.</description>
          <units>g/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="92"/>
                    <count group_id="B3" value="100"/>
                    <count group_id="B4" value="97"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="125"/>
                    <count group_id="B7" value="119"/>
                    <count group_id="B8" value="94"/>
                    <count group_id="B9" value="821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="412.02" spread="507.51"/>
                    <measurement group_id="B2" value="471.01" spread="784.84"/>
                    <measurement group_id="B3" value="402.04" spread="535.44"/>
                    <measurement group_id="B4" value="405.14" spread="702.63"/>
                    <measurement group_id="B5" value="441.16" spread="571.27"/>
                    <measurement group_id="B6" value="450.12" spread="657.04"/>
                    <measurement group_id="B7" value="379.28" spread="457.33"/>
                    <measurement group_id="B8" value="377.28" spread="542.27"/>
                    <measurement group_id="B9" value="417.16" spread="599.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline potassium</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="92"/>
                    <count group_id="B3" value="100"/>
                    <count group_id="B4" value="97"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="125"/>
                    <count group_id="B7" value="119"/>
                    <count group_id="B8" value="94"/>
                    <count group_id="B9" value="821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.323" spread="0.425"/>
                    <measurement group_id="B2" value="4.297" spread="0.426"/>
                    <measurement group_id="B3" value="4.314" spread="0.325"/>
                    <measurement group_id="B4" value="4.311" spread="0.435"/>
                    <measurement group_id="B5" value="4.297" spread="0.420"/>
                    <measurement group_id="B6" value="4.288" spread="0.459"/>
                    <measurement group_id="B7" value="4.294" spread="0.439"/>
                    <measurement group_id="B8" value="4.254" spread="0.479"/>
                    <measurement group_id="B9" value="4.297" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline eGFR</title>
          <description>An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</description>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="92"/>
                    <count group_id="B3" value="100"/>
                    <count group_id="B4" value="97"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="125"/>
                    <count group_id="B7" value="119"/>
                    <count group_id="B8" value="94"/>
                    <count group_id="B9" value="821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.113" spread="21.923"/>
                    <measurement group_id="B2" value="67.425" spread="20.164"/>
                    <measurement group_id="B3" value="67.080" spread="22.205"/>
                    <measurement group_id="B4" value="67.497" spread="21.917"/>
                    <measurement group_id="B5" value="67.042" spread="20.857"/>
                    <measurement group_id="B6" value="67.455" spread="23.646"/>
                    <measurement group_id="B7" value="66.039" spread="22.205"/>
                    <measurement group_id="B8" value="72.213" spread="20.434"/>
                    <measurement group_id="B9" value="67.544" spread="21.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline KDQOL-36 domain score (Effects of Kidney Disease)</title>
          <description>The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (serve problems in all items) to 100 (no problem in all items). &quot;Effects of Kidney disease&quot; subscore was analyzed.</description>
          <population>Participants with valid data for this baseline characteristic</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="97"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="96"/>
                    <count group_id="B6" value="122"/>
                    <count group_id="B7" value="116"/>
                    <count group_id="B8" value="93"/>
                    <count group_id="B9" value="805"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.78" spread="10.28"/>
                    <measurement group_id="B2" value="92.53" spread="9.57"/>
                    <measurement group_id="B3" value="91.78" spread="12.55"/>
                    <measurement group_id="B4" value="92.99" spread="11.04"/>
                    <measurement group_id="B5" value="88.71" spread="16.50"/>
                    <measurement group_id="B6" value="90.45" spread="14.39"/>
                    <measurement group_id="B7" value="89.10" spread="17.45"/>
                    <measurement group_id="B8" value="81.45" spread="20.42"/>
                    <measurement group_id="B9" value="90.57" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline EQ-5D scores (EQ5D - Visual Analog Scale)</title>
          <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).</description>
          <population>Participants with valid data for this baseline characteristic</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="89"/>
                    <count group_id="B3" value="95"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="121"/>
                    <count group_id="B7" value="117"/>
                    <count group_id="B8" value="92"/>
                    <count group_id="B9" value="801"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.76" spread="16.39"/>
                    <measurement group_id="B2" value="72.79" spread="14.81"/>
                    <measurement group_id="B3" value="73.01" spread="16.21"/>
                    <measurement group_id="B4" value="74.49" spread="15.92"/>
                    <measurement group_id="B5" value="73.89" spread="16.47"/>
                    <measurement group_id="B6" value="73.19" spread="16.11"/>
                    <measurement group_id="B7" value="71.36" spread="17.49"/>
                    <measurement group_id="B8" value="70.05" spread="17.69"/>
                    <measurement group_id="B9" value="72.56" spread="16.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratio of UACR at Day 90 to UACR at Baseline</title>
        <description>Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.</description>
        <time_frame>Baseline and Day 90±2</time_frame>
        <population>Full analysis set (FAS): included all participants of the SAF who had baseline and at least one post-baseline UACR value.</population>
        <group_list>
          <group group_id="O1">
            <title>Finerenone (BAY94-8862) (1.25 mg)</title>
            <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) (2.5 mg)</title>
            <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) (5 mg)</title>
            <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) (7.5 mg)</title>
            <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) (10 mg)</title>
            <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) (15 mg)</title>
            <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O7">
            <title>Finerenone (BAY94-8862) (20 mg)</title>
            <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo tablet once daily in the morning for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of UACR at Day 90 to UACR at Baseline</title>
          <description>Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.</description>
          <population>Full analysis set (FAS): included all participants of the SAF who had baseline and at least one post-baseline UACR value.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="123"/>
                <count group_id="O7" value="117"/>
                <count group_id="O8" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.869" spread="0.772" lower_limit="0.772" upper_limit="0.979"/>
                    <measurement group_id="O2" value="0.89" spread="0.786" lower_limit="0.786" upper_limit="1.009"/>
                    <measurement group_id="O3" value="0.824" spread="0.73" lower_limit="0.73" upper_limit="0.929"/>
                    <measurement group_id="O4" value="0.739" spread="0.653" lower_limit="0.653" upper_limit="0.835"/>
                    <measurement group_id="O5" value="0.708" spread="0.627" lower_limit="0.627" upper_limit="0.8"/>
                    <measurement group_id="O6" value="0.63" spread="0.563" lower_limit="0.563" upper_limit="0.705"/>
                    <measurement group_id="O7" value="0.585" spread="0.523" lower_limit="0.523" upper_limit="0.654"/>
                    <measurement group_id="O8" value="0.938" spread="0.829" lower_limit="0.829" upper_limit="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an analysis of covariance (ANCOVA) with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a last-observation carried-forward (LOCF) method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1973</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.926</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.799</ci_lower_limit>
            <ci_upper_limit>1.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2808</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.949</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.818</ci_lower_limit>
            <ci_upper_limit>1.101</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0723</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.878</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.758</ci_lower_limit>
            <ci_upper_limit>1.017</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0039</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.787</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.912</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.755</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.651</ci_lower_limit>
            <ci_upper_limit>0.875</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.671</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.584</ci_lower_limit>
            <ci_upper_limit>0.772</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.624</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.542</ci_lower_limit>
            <ci_upper_limit>0.718</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 90 in Serum Potassium</title>
        <time_frame>Baseline and Day 90±2</time_frame>
        <population>Participants in SAF with valid data for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Finerenone (BAY94-8862) (1.25 mg)</title>
            <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) (2.5 mg)</title>
            <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) (5 mg)</title>
            <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) (7.5 mg)</title>
            <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) (10 mg)</title>
            <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) (15 mg)</title>
            <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O7">
            <title>Finerenone (BAY94-8862) (20 mg)</title>
            <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo tablet once daily in the morning for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 90 in Serum Potassium</title>
          <population>Participants in SAF with valid data for this endpoint</population>
          <units>millimole per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="109"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" lower_limit="0.030" upper_limit="0.187"/>
                    <measurement group_id="O2" value="0.123" lower_limit="0.043" upper_limit="0.203"/>
                    <measurement group_id="O3" value="0.202" lower_limit="0.122" upper_limit="0.282"/>
                    <measurement group_id="O4" value="0.127" lower_limit="0.047" upper_limit="0.207"/>
                    <measurement group_id="O5" value="0.167" lower_limit="0.087" upper_limit="0.248"/>
                    <measurement group_id="O6" value="0.238" lower_limit="0.165" upper_limit="0.31"/>
                    <measurement group_id="O7" value="0.188" lower_limit="0.116" upper_limit="0.259"/>
                    <measurement group_id="O8" value="0.002" lower_limit="-0.077" upper_limit="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0428</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0223</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.305</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0181</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.334</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 90 in eGFR</title>
        <description>An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</description>
        <time_frame>Baseline and Day 90±2</time_frame>
        <population>Participants in SAF with valid data for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Finerenone (BAY94-8862) (1.25 mg)</title>
            <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) (2.5 mg)</title>
            <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) (5 mg)</title>
            <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) (7.5 mg)</title>
            <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) (10 mg)</title>
            <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) (15 mg)</title>
            <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O7">
            <title>Finerenone (BAY94-8862) (20 mg)</title>
            <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo tablet once daily in the morning for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 90 in eGFR</title>
          <description>An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</description>
          <population>Participants in SAF with valid data for this endpoint</population>
          <units>mL/min/1.73m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="113"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.364" spread="-4.311" lower_limit="-4.311" upper_limit="-0.418"/>
                    <measurement group_id="O2" value="-3.189" spread="-5.164" lower_limit="-5.164" upper_limit="-1.213"/>
                    <measurement group_id="O3" value="-2.497" spread="-4.475" lower_limit="-4.475" upper_limit="-0.518"/>
                    <measurement group_id="O4" value="-3.378" spread="-5.341" lower_limit="-5.341" upper_limit="-1.415"/>
                    <measurement group_id="O5" value="-4.192" spread="-6.181" lower_limit="-6.181" upper_limit="-2.202"/>
                    <measurement group_id="O6" value="-3.806" spread="-5.563" lower_limit="-5.563" upper_limit="-2.05"/>
                    <measurement group_id="O7" value="-4.024" spread="-5.792" lower_limit="-5.792" upper_limit="-2.256"/>
                    <measurement group_id="O8" value="-1.578" spread="-3.53" lower_limit="-3.53" upper_limit="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5454</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.786</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.337</ci_lower_limit>
            <ci_upper_limit>1.765</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2186</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.177</ci_lower_limit>
            <ci_upper_limit>0.957</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4859</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.918</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.503</ci_lower_limit>
            <ci_upper_limit>1.667</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1677</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.358</ci_lower_limit>
            <ci_upper_limit>0.759</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0462</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.613</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.183</ci_lower_limit>
            <ci_upper_limit>-0.044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0705</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.228</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.643</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.446</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.869</ci_lower_limit>
            <ci_upper_limit>-0.022</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)</title>
        <description>The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). &quot;Effects of Kidney disease&quot; subscore was analyzed.</description>
        <time_frame>Baseline and Day 90±2</time_frame>
        <population>Participants in FAS with valid data for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Finerenone (BAY94-8862) (1.25 mg)</title>
            <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) (2.5 mg)</title>
            <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) (5 mg)</title>
            <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) (7.5 mg)</title>
            <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) (10 mg)</title>
            <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) (15 mg)</title>
            <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O7">
            <title>Finerenone (BAY94-8862) (20 mg)</title>
            <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo tablet once daily in the morning for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)</title>
          <description>The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). &quot;Effects of Kidney disease&quot; subscore was analyzed.</description>
          <population>Participants in FAS with valid data for this endpoint</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="113"/>
                <count group_id="O7" value="109"/>
                <count group_id="O8" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.116" spread="-4.521" lower_limit="-4.521" upper_limit="0.289"/>
                    <measurement group_id="O2" value="0.104" spread="-2.369" lower_limit="-2.369" upper_limit="2.577"/>
                    <measurement group_id="O3" value="-1.229" spread="-3.643" lower_limit="-3.643" upper_limit="1.185"/>
                    <measurement group_id="O4" value="-1.185" spread="-3.597" lower_limit="-3.597" upper_limit="1.226"/>
                    <measurement group_id="O5" value="-2.596" spread="-5.049" lower_limit="-5.049" upper_limit="-0.142"/>
                    <measurement group_id="O6" value="0.112" spread="-2.054" lower_limit="-2.054" upper_limit="2.278"/>
                    <measurement group_id="O7" value="0.058" spread="-2.146" lower_limit="-2.146" upper_limit="2.263"/>
                    <measurement group_id="O8" value="0.747" spread="-1.684" lower_limit="-1.684" upper_limit="3.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0757</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-2.863</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.022</ci_lower_limit>
            <ci_upper_limit>0.297</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6941</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-0.643</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.851</ci_lower_limit>
            <ci_upper_limit>2.565</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2228</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.976</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.155</ci_lower_limit>
            <ci_upper_limit>1.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2313</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.932</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.098</ci_lower_limit>
            <ci_upper_limit>1.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0386</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-3.342</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.509</ci_lower_limit>
            <ci_upper_limit>-0.176</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-0.634</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.624</ci_lower_limit>
            <ci_upper_limit>2.355</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6536</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-0.688</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.699</ci_lower_limit>
            <ci_upper_limit>2.322</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)</title>
        <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).</description>
        <time_frame>Baseline and Day 90±2</time_frame>
        <population>Participants in FAS with valid data for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Finerenone (BAY94-8862) (1.25 mg)</title>
            <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) (2.5 mg)</title>
            <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) (5 mg)</title>
            <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) (7.5 mg)</title>
            <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) (10 mg)</title>
            <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) (15 mg)</title>
            <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days.</description>
          </group>
          <group group_id="O7">
            <title>Finerenone (BAY94-8862) (20 mg)</title>
            <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo tablet once daily in the morning for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)</title>
          <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).</description>
          <population>Participants in FAS with valid data for this endpoint</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="112"/>
                <count group_id="O7" value="109"/>
                <count group_id="O8" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.381" spread="-1.22" lower_limit="-1.22" upper_limit="3.982"/>
                    <measurement group_id="O2" value="3.888" spread="1.208" lower_limit="1.208" upper_limit="6.568"/>
                    <measurement group_id="O3" value="3.124" spread="0.494" lower_limit="0.494" upper_limit="5.754"/>
                    <measurement group_id="O4" value="2.851" spread="0.241" lower_limit="0.241" upper_limit="5.461"/>
                    <measurement group_id="O5" value="2.698" spread="0.026" lower_limit="0.026" upper_limit="5.37"/>
                    <measurement group_id="O6" value="2.743" spread="0.394" lower_limit="0.394" upper_limit="5.092"/>
                    <measurement group_id="O7" value="1.914" spread="-0.465" lower_limit="-0.465" upper_limit="4.292"/>
                    <measurement group_id="O8" value="4.425" spread="1.794" lower_limit="1.794" upper_limit="7.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0816</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-3.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.471</ci_lower_limit>
            <ci_upper_limit>0.383</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7625</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-0.537</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.027</ci_lower_limit>
            <ci_upper_limit>2.953</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.4603</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.301</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.759</ci_lower_limit>
            <ci_upper_limit>2.157</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3678</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.574</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.004</ci_lower_limit>
            <ci_upper_limit>1.855</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3279</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.727</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.191</ci_lower_limit>
            <ci_upper_limit>1.736</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3102</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.682</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.935</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1317</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-2.511</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.778</ci_lower_limit>
            <ci_upper_limit>0.755</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 93 days after the start of study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Finerenone (BAY94-8862) (1.25 mg)</title>
          <description>1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E2">
          <title>Finerenone (BAY94-8862)(2.5 mg)</title>
          <description>2.5 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E3">
          <title>Finerenone (BAY94-8862)(5 mg)</title>
          <description>5 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E4">
          <title>Finerenone (BAY94-8862)(7.5 mg)</title>
          <description>7.5 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E5">
          <title>Finerenone (BAY94-8862)(10 mg)</title>
          <description>10 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E6">
          <title>Finerenone (BAY94-8862)(15 mg)</title>
          <description>15 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E7">
          <title>Finerenone (BAY94-8862)(20 mg)</title>
          <description>20 mg BAY94-8862 tablet once daily in the morning for 90 days</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Placebo tablet once daily in the morning for 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer AG</organization>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

